Tech Company Financing Transactions
Kalypsys Funding Round
On 11/29/2006, Kalypsys raised $100 million in Series C funding from Tavistock Life Sciences, KT Venture Group and Presidio Partners.
Transaction Overview
Company Name
Announced On
11/29/2006
Transaction Type
Venture Equity
Amount
$100,000,000
Round
Series C
Investors
Tavistock Life Sciences (Lead Investor) (Shehan Dissanayake)
Proceeds Purpose
The company will use the proceeds to fund its broad range of preclinical and clinical programs in the areas of cardiovascular/metabolic diseases, pain/inflammation and oncology.
Company Information
Company Status
Out of Business
Industry
Biopharmaceutical
Mailing Address
380 Stevens Ave. 313
Solana Beach, CA 92075
USA
Solana Beach, CA 92075
USA
Phone
Website
Email Address
Overview
A suite of ultra-high throughput screening, chemical, biological, and informatics technologies that permits it to operate as a fully integrated drug discovery company.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Stewart Noble
Chief Medical Officer
Mary Spellman
VP - Bus. Development
Simon Tomlinson
VP - Finance
Dana Zhang
VP - Operations
Inge Bear
VP - R & D
John Fikes
Browse more venture capital transactions:
Prev: 11/29/2006: VPIsystems venture capital transaction
Next: 11/29/2006: Crisp Media venture capital transaction
Share this article
About Our VC Transactions Data
We do our best to document all VC transactions involving tech companies. VC investment data records on this site are derived from company press releases and news coverage. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs